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Abstract 
Objective: In 2016 there were an estimated 56,870 new cases of thyroid cancer (TC) in the United 
States. Fine needle aspiration cytology (FNAC) is the most safe, accurate and cost-effective method 
for the initial investigation of thyroid nodules. FNAC is limited by the inability to accurately diagnose 
malignancy in follicular-patterned lesions, and as a result 20% to 30% of cases under investigation 
for TC are classified as cytologically indeterminate, illustrating a problem with current FNAC 
procedure. Raman spectroscopy has shown promising results for the detection of many cancers 
however to date there has been no report on the performance of Raman spectroscopy on thyroid 
cytological samples. The aim of this study was to examine whether Raman spectroscopy could be 
used to correctly classify cell lines representing benign thyroid cells and various subtypes of TC. 
Methods: A benign thyroid cell line and seven TC cell lines were prepared as ThinPrep® cytology 
slides and analysed with Raman spectroscopy. Principal components analysis (PCA) and linear 
discriminant analysis (LDA) were implemented to develop effective diagnostic algorithms for 
classification of Raman spectra of different TC subtypes.  
Results: The spectral differences separating benign and TC cell lines were assigned to differences in 
the composition of nucleic acids, lipids, carbohydrates and protein in the benign and cancer cells. 
Good sensitivities (74 - 85%), specificities (65 - 93%) and diagnostic accuracies (71 – 88%) were 
achieved for the identification of TC.  
Conclusion: These findings suggest that Raman spectroscopy has potential for preoperative TC 
diagnosis on FNAC samples. 
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Introduction 
In 2016 there were an estimated 56,870 new cases of thyroid cancer (TC) in the United States
1
. 
Women account for approximately 75% of these cases, exhibiting a substantially higher rate of 
incidence of the disease compared to men, but similar mortality. TC incidence has been steadily 
increasing in recent decades, as reported in the TC epidemiology studies
2,3
. Although improved 
diagnostic methods, notably ultrasound (US) examination, are the likely reason for the global 
increase in incidence (especially of smaller nodules), recent studies show that the incidence of 
aggressive forms associated with higher mortality is also increasing
4
.  
Of the wide array of malignancies that are characterised as TC, papillary thyroid carcinoma (PTC) is 
the most common, accounting for approximately 80% of cases. Other histological types include 
follicular thyroid carcinoma (FTC), Hürthle cell carcinoma, poorly differentiated carcinoma, 
medullary thyroid carcinoma (MTC), and undifferentiated or anaplastic carcinoma (UTC or ATC, 
respectively). PTC and FTC emanate from thyroid follicular epithelial cells and are commonly 
referred to as well differentiated thyroid carcinomas (DTC) 
5,6
. MTCs are derived from 
neuroendocrine cells and represent approximately 5 to 10% of TC
7
. 
The most common manifestation of TC is as a thyroid nodule. Thyroid nodules are common in the 
general population, with a prevalence of 2-7% when detected by palpation and 50% when searched 
for using US examination 
5,8
. Despite thyroid nodules having a high incidence rate, approximately 
60%-80% are classified as benign, with only 3.5% - 10% presenting as malignancies. Fine needle 
aspiration cytology (FNAC) is the most accurate and cost-effective method for the initial 
management of thyroid nodules, and its accuracy is higher when it is conducted under US guidance. 
FNAC is limited by the inability to accurately diagnose malignancy in follicular-patterned lesions, and 
as a result more than 20% of cases under investigation for TC are classified as cytologically 
“indeterminate” 9–12. The indeterminate category often requires surgical resection to definitively 
exclude malignancy; however, since approximately 70% of these lesions are finally shown to be 
benign, surgery is an unnecessary procedure for the vast majority of cases 
13,14
.  
In an attempt to overcome limitations of cytology in the detection of cancer, optical spectroscopic 
techniques have been investigated as adjunct or alternative approaches
15
. Optical spectroscopic 
methods use the interaction of light with matter to provide a detailed description of the molecular 
composition of biological tissue, and so these techniques can be employed to detect biochemical 
profiles associated with health or disease.  
Raman spectroscopy is a form of vibrational spectroscopy based on inelastic scattering. Raman 
spectra are obtained by irradiating a sample with monochromatic laser light, which interacts with 
molecules within the sample and induces molecular vibrations. The change in energy between the 
incident and inelastically scattered light is called the Raman shift. The Raman spectrum is a plot of 
the intensity of the scattered light versus the change in energy, given in wavenumbers, cm
-116–18
. The 
spectrum produced by the probed molecular vibrations represents a detailed biochemical 
fingerprint of the cellular components. 
Raman spectroscopy has shown promising results for the detection of multiple cancers including 
cervical, gastrointestinal, breast, brain, and lung cancer
19–22
. The application of Raman spectroscopy 
for TC diagnosis has also been investigated in studies utilizing cell lines
23,24,25
, and tissue sections
26–32
. 
Harris et al.
23
 applied Raman spectroscopy to two thyroid cell lines, one cancer cell line (8505C, 
representing UTC) and one benign cell line (Nthy-ori 3-1), to analyse the cellular differences between 
benign and malignant cells. Distinct differences in the nucleic acid content of the cancer cells were 
revealed, and, using neural network analysis a diagnostic sensitivity of 95% was achieved for 
discrimination of the cancer cell line. Building on Harris’ work, Lones et al.24 applied Raman 
spectroscopy to analyse one benign thyroid cell line and four TC cell lines representing PTC, FTC, 
MTC and UTC. Alterations in either the molecular conformation or concentration of DNA/RNA, 
amide I and aromatic amino acids were found to be indicative of cancer. The authors reported good 
discrimination of the benign cell line from MTC and UTC, and a lower discrimination between cell 
lines with the same cell of origin, namely benign versus DTC cell lines. 
Recent studies have also investigated the feasibility of applying Raman spectroscopy to thyroid 
tissue samples to detect cancer. These studies used multivariate statistical analysis of Raman spectra 
to achieve high diagnostic sensitivities and specificities for discrimination between healthy thyroid 
tissue and TC, and follicular patterned thyroid
27–30
.  
Application of Raman spectroscopy to thyroid FNAC has not yet been reported. As a first step, the 
present proof-of-concept study builds on the aforementioned studies by investigating the 
application of Raman spectroscopy to a benign thyroid cell line and a large number of TC cell lines 
prepared as ThinPrep® cytology slides, representing FNAC cytological specimens. 
 
Materials and Methods 
Cell cultures 
Cell lines used were representative of benign thyroid cells and four subtypes of TC: one benign 
follicular epithelial cell line (NThy-ori 3-1), two PTC cell lines (K1 and TPC1), one FTC cell line (XTC1), 
two UTC cell lines (8505C and C643) and two MTC lines (CRL-1803TT and MZCRC1). The Nthy-ori 3-1 
cell line [catalog no. 90011609, lot no. 13B007, passage no. 16 (p16)] was purchased from Sigma and 
used at p18. The TT cell line was obtained from the American Type Culture Collection (ATCC CRL1803 
TT, lot no. 58785858, no passage information) and was used at p3. All other cell lines (K1, used at p9; 
TPC1, used at p29; XTC1, used at p17; 8505C used at p21; C643, used at p31; MZCRC1, used at p14 
were kindly provided by Prof. Paula Soares (Institute of Molecular Pathology and Immunology of the 
University of Porto, Portugal). All cell lines were maintained in standard culture conditions at 37°C in 
a humidified incubator under 5% carbon dioxide. RPMI-1640 with 10% fetal bovine serum (FBS) and 
1% Pen-Strep was the medium for most cell lines, with the following exceptions: K1 cells were 
cultured in DMEM/F12 medium supplemented with 10% FBS; CRL1803TT cells were cultured in F-
12K Nutrient Mixture Kaighn's Modification with 10% FBS; MZCRC1 cells were cultured in DMEM 
with 15% FBS. All culture media were from Invitrogen. Slides for Raman analysis were prepared 
using a ThinPrep® processor and air dried without final staining. 
 
Raman Measurement 
Raman spectra were acquired using a HORIBA Jobin Yvon XploRA
TM
 system (Villeneuve d’Ascq, 
France) which consists of an Olympus microscope BX41 supplied with a x100 objective (MPlanN, 
Olympus, NA = 0.9). A 532 nm diode laser source was utilised during the study and was set at 100% 
power, which gave 8 mW at the objective. The confocal hole was set at 100 µm and coupled to a slit 
of aperture 100 µm. The system was calibrated to the 520 cm
-1
 spectral line of Silicon and the 1200 
lines per mm grating was used. Backscattered light was detected using an air-cooled CCD detector 
(Andor, 1024 x 256 pixels). The software implemented to manage the spectrometer was Labspec 
V5.0.   
Thirty cells were recorded from each slide. For each cell, a single spectrum was recorded from the 
cell nucleus, corresponding to the average of two accumulations of 30 seconds. Spectra were also 
recorded from 30 vacant locations on a ThinPrep® glass slide with identical exposure time in order to 
obtain representative background glass spectra.   
The signal to noise ratio (SNR) was calculated by dividing the difference between the peak signal at 
1665 cm
-1
 and the baseline intensity (smooth region after 400 cm
-1
) by the standard deviation of the 
peak signal, as described by Desroches et al
33
. The mean SNR of all of the spectra included was 102 
dB, which was calculated from a range of 77 - 159 dB. 
 
Data pre-processing and analysis 
All spectral data analysis was conducted using R software. Pre-processing involved smoothing 
(Savitzy Golay k=5, w=15), a fifth-order polynomial baseline correction and vector normalisation. 
Outliers were removed using a Grubbs filter. A non-negatively constrained least squares (NNLS) 
method was used to remove interfering signals from the glass substrate
34,35
. As described by Ibrahim 
et al.
31
, spectra from cellular components, such as nucleic acids, proteins, lipids etc, and the 
independently recorded glass spectra were used to fit the sample spectra and remove the glass 
contribution. The data was analysed using Principal Component Analysis (PCA), an unsupervised 
method which reduces the dimensionality of the data and retains the data which are of greatest 
importance, known as principal components (PC)
36
. Linear discriminant analysis (LDA), which 
maximises the separation between different classes and minimises within-class variance, was used 
together with PCA to develop classification model.  When implemented with PCA, LDA uses the PC 
scores to develop the classification model 
36–38
.  The first PCs that explained approximately 95% of 
the variance within the data were used in the PC-LDA classification models. 
 
Results 
Mean spectral analysis 
Figure 1 depicts the mean benign thyrocyte cell line (Nthy-ori3-1) spectrum and the biological 
components corresponding to each spectral region. The standard deviation shows that there was 
minimal variation between the spectra from individual cells and this was also the case for all cell 
lines. The features in the TC cell line spectra that differ from the benign cell line are demonstrated 
by the difference spectra in Figures 2-4. 
The significant Raman peaks and their corresponding biological components are shown in Table 1. 
Spectral differences between the benign thyroid cell line and the TC cell lines corresponded to peaks 
relative to lipids and proteins (524, 820, 1225, 1278, 1310, 1343, 1402, 1435, 1453, 1570, 1661, 1677 
cm
-1
), carbohydrates (477, 941, 1343 cm
-1
), phosphates (1190 cm
-1
) and nucleic acids (780, 1330 cm
-
1
), as shown in Figures 2-4. The difference spectra of the FTC and PTC cell lines had similar profiles, 
with significant peaks at 1225, 1435, 1456 and 1690 cm
-1
 differentiating them from the benign cell 
line (Figure 2).  For the UTC cell lines, consistent spectral differences were observed at 780, 1343, 
1190, 1280, 1450 cm
-1
 (Figure 3). Compared to the benign cell line, the MTC cell lines showed 
consistent spectral differences at 780, 1450, 1570, 1645, and 1673 cm
-1
 (Figure 4).  
 
Linear Discriminant Analysis 
In order to evaluate the efficacy of Raman spectroscopy to accurately classify the benign and TC cell 
lines, PC-LDA classification models were developed using the principal components from PCA of the 
benign thyroid cell line and each of the TC cell lines. Table 2 shows the results of seven separate PC-
LDA models used to classify the benign thyroid cells and each of the TC cell lines. The performance of 
each two way classification is shown using the sensitivity, specificity and diagnostic accuracy of each 
model. Diagnostic accuracy is used to describe the proportion of correctly classified spectra (true 
positive + true negative) among all the classified spectra (true positive + true negative + false 
positive + false negative)
39
. The first 5 PCs in each case were used to develop the PC-LDA classifiers. 
PC-LDA classification of Nthy-ori 3-1 (benign) vs. PTC, FTC and MTC cell lines yielded sensitivities of 
≥90%, specificities of ≥80% and accuracies of ≥89%. Lower performance was observed for the 
models discriminating the benign cell line from the UTC cell lines with sensitivity, specificity, and 
diagnostic accuracy of 77%, 73% and 75% for 8505C, and 87%, 77%, 82% for C643, respectively.  
To evaluate the ability of PC-LDA to discriminate benign cells from TC subtypes, cell lines were 
grouped by their TC subtype. To produce an unbiased classifier, representative spectra from each 
cell line were selected at random and combined by TC subtype, matching the number of spectra 
used for the benign cell line. As XTC1 was the only cell line representing FTC, all spectra from this cell 
line were used, matching the number of spectra used for the benign cell line. Table 3 shows the 
results achieved for discriminating the benign cell line from the TC cell lines grouped by subtype. 
Separate two-way classification models using 5 PCs each were developed to discriminate the benign 
cells from each TC subtype. The MTC and PTC subtypes were discriminated from the benign cell line 
with diagnostic accuracies of at least 82%. The UTC subtype was classified at a lower accuracy of 
71%. Due to similarities in their cellular biochemistry observed in this study, the well differentiated 
PTC and FTC subtypes were grouped together for analysis, yielding a diagnostic accuracy of 74%. 
Table 4 shows the results of the two-way PC-LDA classification models used for the discrimination of 
the PTC and UTC cell lines, each was developed using 4 PCs. Each two-way classification model 
yielded sensitivities, specificities and diagnostic accuracies above 92% for each cell line classification. 
Grouped together, the PTC and UTC subtypes were discriminated with a diagnostic accuracy of 81%. 
Table 5 shows the results for the PC-LDA classification of MTC cell lines versus the PTC cell lines. 
Each classification is the result of separate two-way models using 4 PCs each. The models yielded 
specificities and diagnostic accuracies ≥93% for each cell line classification, and a diagnostic accuracy 
of 86% for the two-way discrimination of the MTC and PTC subtypes. 
Table 6 shows the performance of separate two-way PC-LDA models in discriminating FTC cell lines 
from PTC, MTC and UTC cell lines. Discrimination of the follicular XTC1 cell line from the PTC cell 
lines was achieved using 4 PCs in each PC-LDA model. Diagnostic accuracies of 87% and 85% were 
obtained for the K1 and TPC1 cell lines respectively. The FTC cell line was discriminated from the UTC 
cell lines with diagnostic accuracies above 94%, and from the MTC cell lines with 100% accuracy, 
each model using 4 PCs. When cell lines were grouped by subtype, FTC was distinguished from MTC 
with an accuracy of 99% (using 4 PCs), from UTC with a diagnostic accuracy of 89% (using 3 PCs), and 
from PTC with 79% accuracy (using 5 PCs). 
Table 7 summarises the results achieved for separate two-way classifications of the MTC and UTC 
cell lines. The MTC cell lines were discriminated from the UTC cell lines with diagnostic accuracies 
≥97% using 3 PCs in each model, and when grouped together, the MTC cell lines were discriminated 
from the UTC cell lines with an accuracy of 84% using 4 PCs. 
Table 8 demonstrates the performance of a five-way classification model developed using the 
benign cell spectra and spectra from all the TC subtypes. Representative spectra from each cell line 
were selected at random and combined into TC subtypes as previously described. The model yielded 
diagnostic sensitivities from 57-100%, specificities ≥91%, and an overall diagnostic accuracy of 78% 
using 5 PCs. Figure 5 depicts the scatter plot of the linear discriminant scores of the benign spectra 
and spectra from each TC subtype. The FTC spectra and the PTC spectra form two close clusters 
using the first two discriminant functions, which can be discriminated from the benign spectra with 
some overlap. The MTC spectra form a cluster along the first discriminant function which is distinct 
from the benign spectra. The UTC subtype clusters adjacent to the benign spectra along the first 
discriminant function, although using only the first two discriminant functions to plot the scatter plot 
of the linear discriminant scores, the UTC and benign spectra overlap. 
Table 9 shows the performance of the PC-LDA model in discriminating the benign cell line from all of 
the TC subtypes combined into one group. As before, in order to produce an unbiased classifier, 
representative spectra from each TC subtype were selected at random and combined into one TC 
group, giving a total number of TC spectra that was similar to the number of benign spectra. The first 
5 PCs were used to develop the two-way PC-LDA model which produced a sensitivity of 74%, 
specificity of 87%, and overall accuracy of 81% for discriminating benign spectra from the TC spectra.  
 
 
Discussion 
Raman microspectroscopy was performed in this study to obtain a biomolecular characterisation of 
eight thyroid cell lines. Spectral differences were consistently observed between the benign and TC 
cell lines with the strongest signals occurring at ~470, ~780, 855, 941, ~1230, 1278, 1343, 1402, 
1436, 1456, 1571, 1650, 1690 and 1677 cm
-1
, representing significant differences in the molecular 
composition of carbohydrates, nucleic acids, lipids, protein structures and amides, as mapped by 
Movasaghi et al.
40
, across the benign and TC cell lines. These peaks differentiating benign thyroid 
cells and TC cells are in accordance with several of the characteristic TC peaks identified in previous 
studies using tissue samples and cell lines
23,24,31
. The consistent spectral differences between the 
benign and TC cell lines observed in our study may be reflective of the malignant transformation 
that occurs due to the carcinogenic progression of TC
40,41
. These Raman peaks represent the 
vibrational modes of biomolecules that are altered in quantity or conformation in the malignant 
cells.  
The difference spectrum between the benign cell line and the FTC cell line (XTC1), shows identical 
strong bands to the difference spectra between the benign cell line and the PTC cell lines. The similar 
profiles of the difference spectra reveal a comparable biochemistry in the FTC and PTC subtypes. In 
comparison to the benign cell line, the PTC and FTC cell lines showed an increased peak intensity at 
1225 cm
-1
 and 1435 cm
-1
, and a decreased peak intensity at 1456 cm
-1
 and 1690 cm
-1
. This indicates 
an increase in the level of amide III, proteins, and nucleic acids, and a decrease in the amount of 
lipids and amide I in the cancer cells
40
. The spectral profile of these DTC cell lines show similarities to 
the characteristic FTC peaks identified in a study by Teixeira et al. using thyroid tissue
30
. As both PTC 
and FTC emanate from epithelial follicular cells and are often even analysed as one group in terms of 
prognosis, it is plausible that the similarities in their biochemistry observed may be explained by the 
common origin of PTC and FTC
5,6
. 
Regarding the UTC cell lines (8505C and C643), both exhibited elevated nucleic acids (~1343 cm
-1
) 
and polysaccharides (477 cm
-1
) in comparison to the benign cell line. A lower peak intensity for 
amide III was observed for both cell lines in comparison to the benign cell line, which is evident by 
the broad band in the difference spectrum between ~1190 cm
-1
 and 1280 cm
-1
. The 8505C cell line 
showed an increased peak intensity at both 780 cm
-1
 and 830 cm
-1
, corresponding to increased 
nucleic acids, which is consistent with the findings of Harris et al
23
. The 8505C cell line also showed a 
higher peak intensity at 1450 cm
-1
 in comparison to the benign cell line, which suggests an increase 
in the level of proteins and lipids in the cancer cells
40
. UTC is a heterogenous disease at a molecular 
level, making it difficult to find commonalities between cases, which may explain the dissimilarities 
in the spectral profiles observed in this study between the two UTC cell lines
42
. 
The difference spectra of the benign versus the MTC cell lines (MZCRC1 and CRL1803TT) showed 
consistent spectral bands at 780, 1450, 1570, 1645, and 1673 cm
-1
 that differentiate the MTC cell 
lines from the benign cell line. In comparison to the benign cell line, the MTC cell lines exhibited a 
lower peak intensity at 1450 cm
-1
,
 
indicating lower levels of lipids, carbohydrates and amino acids in 
the MTC cells. In comparison to the benign cell line, both MTC cell lines exhibited greater peak 
intensities at 780 cm
-1
, 1570 cm
-1
and 1670 cm
-1
, indicating an increase in the level of nucleic acids 
(780 cm
-1
), aspartate and glutamate (1570 cm
-1
), and amide I (1670 cm
-1
). As MTCs emanate from 
the neuroendocrine parafollicular C cells and not from the follicular epithelial cells like the other cell 
lines, the distinct overlapping spectral features that differentiate the MZCRC1 and CRL1803TT cell 
lines from the benign cell line may be explained by the distinct origin of MTC
7
.  
The main focus of this investigation was to evaluate the potential use of Raman spectroscopy as an 
enhanced diagnostic technique for TC. Objective comparative analysis of the spectra was achieved 
using linear discriminant analysis (LDA) on already PCA-transformed data sets for maximum class 
separation. Application of the PC-LDA algorithm to the data achieved diagnostic accuracies up to 
99% for the distinction of benign and TC cell lines. The well differentiated PTC and FTC cell lines were 
detected with sensitivities >90% and specificities >80%, although the model yielded lower 
performance scores for identifying the UTC cell lines (sensitivities of 77 and 87%, specificities of 73 
and 77%, and diagnostic accuracies of 75 and 82% for the 8505C and C643 cell lines, respectively). 
The heterogeneity and wide variability of molecular profiles of UTCs may explain the poorer 
performance of the model for discriminating benign cells from individual UTC cell lines as well as the 
grouped UTC cell lines (diagnostic accuracy of 71%).  
A PC-LDA model was applied to examine whether Raman spectroscopy could be used to correctly 
classify cell lines representing the various subtypes of TC. Diagnostic accuracies from 92%-97% were 
achieved for the discrimination of the UTC cell lines from FTC and PTC cell lines. The MTC cell lines 
were discriminated from the PTC, FTC and UTC cell lines with classification model performance 
scores >93%. The high accuracy observed for the classification of the MTC cell lines may be due to 
the different origin of MTCs from other TCs, as discussed previously. FTC (XTC1) and PTC (K1) cell 
lines were discriminated with an accuracy of 87% and the FTC cell line (XTC1) and PTC cell line (TPC1) 
were discriminated with an accuracy of 85%. Cell lines from the same subtype of TC were then 
grouped together for analysis. Diagnostic accuracies >81% were achieved for discriminating UTC 
from the PTC, FTC and MTC subtypes. The model also retained a high level of performance for the 
discrimination of the MTC subtype from PTC and FTC, with respective diagnostic accuracies of 86 
and 99%. The well differentiated PTC and FTC subtypes were then discriminated with a marginally 
lower diagnostic accuracy of 79%, which may be explained by the common origin of PTC and FTC.  
PC-LDA was then applied to investigate the ability to discriminate the benign cells and all the TC 
subtypes within the same model. The model yielded a poor sensitivity (57%) for the benign cells as 
benign spectra were misclassified as PTC. Multiple PTC spectra were classified as FTC, resulting in a 
low diagnostic sensitivity of 63% for PTC. The low discrimination accuracy achieved in this study 
between cells derived from the same origin is similar to the findings of Lones et al
24
. The MTC and 
FTC subtypes were discriminated with sensitivities of 100 and 94% respectively, as observed visually 
in the scatter plot of the linear discriminant scores. The model also yielded a sensitivity of 79% for 
the UTC subtype. Multiple UTC spectra were misclassified as PTC and benign, as observed in the 
overlap of the clusters of these subtypes in the scatter plot of the linear discriminant scores. 
The benign thyroid cell line could be discriminated from all of the TC subtypes combined into one 
group with a diagnostic accuracy of 81%. This is slightly higher than the 78.3% reported by Medeiros 
Neto et al.
31
, which was achieved applying PC-LDA to Raman spectra obtained from patient thyroid 
tissue.  
The paramount information required from the thyroid FNAC procedure is the differentiation 
between benign and malignant thyroid nodules. FNAC is the current favoured diagnostic method for 
the initial investigation of thyroid nodules, with reported sensitivity and specificity ranges of 65%-
98% and 78%-100%, respectively
43–46
.  The results of this study show that Raman spectroscopy may 
also be utilized to improve the accuracy of FNAC. In our study, good sensitivities (63%-100%), 
specificities (65%-100%) and diagnostic accuracies (71%-99%) were achieved for the identification of 
TC using Raman spectroscopy on TC cell lines prepared as ThinPrep® cytology slides. In conclusion, 
these data suggests a high potential for using Raman spectroscopy to improve the preoperative 
diagnosis of TC on FNAC samples; studies are thus warranted to directly test this application.  
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Tables 
Table 1. Tentative peak assignments for the significant Raman bands identified by spectral variation 
analysis
40,47
.  
Wavenumber 
(cm
-1
) 
Raman peak assignments 
430 Cholesterol ester 
454 Ring torsion of phenyl 
477 Polysaccharides 
509 S-S disulphide stretching band of collagen 
524 S-S disulphide stretching in proteins 
Phosphatidylserine 
614 Cholesterol ester 
645 C-C twisting mode of phenylalanine 
700 Amino acid methionine 
729 Adenine 
780 Uracil based ring breathing mode 
820 Protein band  
Structural protein modes of tumours 
Collagen  I 
855 Proline, tyrosine 
880 Tryptophan  
941 Skeletal modes of polysaccharides 
970 Phosphate monoester groups of phosphorylated proteins and nucleic acids 
~1000 Phenylalanine 
1100-375 Several bands of moderate intensity belonging to amide III and other proteins 
1310 CH3/CH2 twisting or bending mode of lipid/ 
collagen 
1230 Antisymmetric phosphate stretching vibration 
1330 Region associated with DNA & phospholipids  
Collagen 
1343 CH3,CH2 wagging (collagen assignment) 
Glucose 
CH residual vibrations 
1392 C-N stretching, in quinoid ring-benzoid 
ring-quinoid ring 
1402 Bending modes of methyl groups 
Amino acids aspartic and glutamic acid 
1436 CH
2
 scissoring 
1450 C-H deformation bands (CH functional groups in lipids, amino acids side chains of the 
proteins and carbohydrates) 
1453 Protein bands 
Structural protein modes of tumors 
1499 C=C stretching in benzenoid ring  
1570 COO- 
Aspartate and glutamate 
1645 Amide I (α helix) 
1650 C=C Amide I 
Protein amide I absorption 
1667 Protein band 
Carbonyl stretch C=O 
1677 Amide I (proteins) 
C=O stretching (lipids) 
T, G, C ring breathing modes of DNA/RNA bases 
 
 
Table 2. Performance of the PC-LDA classification model in discriminating the benign thyroid 
follicular cell line Nthy-ori 3-1 from each TC cell line. 
TC cell line distinguished 
from Nthy-ori 3-1 
Subtype of 
TC 
Sensitivity 
(%) 
Specificity 
(%) 
Diagnostic 
accuracy (%) 
XTC1  FTC 100 80 90 
K1  PTC 90 87 89 
TPC1  PTC 97 87 92 
8505C  UTC 77 73 75 
C643  UTC 87 77 82 
MZCRC1 MTC 100 97 99 
CRL-1803TT MTC 100 93 97 
 
 
 
 
 
 
 
Table 3.  Performance of the PC-LDA classification model in discriminating the benign thyroid 
follicular cell line Nthy-ori 3-1 from TC cell lines grouped by TC subtype. 
TC subtype distinguished 
from Nthy-ori 3-1 
Sensitivity 
(%) 
Specficity 
(%) 
Diagnostic 
accuracy (%) 
PTC
†
 85 79 82 
UTC
‡
 77 65 71 
MTC
§
 84 93 89 
DTC
¶
 74 74 74 
†
PTC includes K1 and TPC1. 
‡
UTC includes 8505C and C643. 
§
MTC includes CRL1803TT and MZCRC1.
 ¶
DTC 
includes PTC (K1 and TPC1) and FTC (XTC1). 
 
 
Table 4. Performance of the PC-LDA classification model in discriminating PTC from UTC cell lines.  
Comparison Sensitivity 
(%) 
Specificity 
(%) 
Diagnostic 
accuracy (%) 
K1 vs. 8505C 93 90 92 
K1 vs. C643 93 97 95 
TPC1 vs. 8505C 97 93 95 
TPC1 vs. C643 93 93 93 
PTC
†
 vs. UTC
‡ 80 82 81 
†
PTC includes K1 and TPC1, 
‡
UTC includes 8505C and C643 
 
 
Table 5.  Performance of the PC-LDA classification model in discriminating MTC from PTC cell lines. 
Comparison Sensitivity 
(%) 
Specificity 
(%) 
Diagnostic 
accuracy (%) 
CRL1803TT vs. K1 100 97 99 
MZCRC1 vs. K1 100 93 97 
CRL1803TT vs. TPC1 100 100 100 
MZCRC1 vs. TPC1 100 100 100 
MTC
†
 vs. PTC
‡ 90 82 86 
†
MTC includes CRL1803TT and MZCRC1. 
‡
PTC includes K1 and TPC1. 
 
 
 
Table 6. Performance of PC-LDA classification of FTC lines from PTC, MTC and UTC cell lines. 
Comparison Sensitivity (%) Specificity (%) Diagnostic accuracy (%) 
XTC1 vs. K1 97 77 87 
XTC1 vs. TPC1 89 80 85 
XTC1 vs. 8505C 100 87 94 
XTC1 vs. C643 97 97 97 
XTC1 vs. CRL1803TT 100 100 100 
XTC1 vs. MZCRC1 100 100 100 
FTC
†
 vs. PTC
‡ 89 69 79 
FTC
†
 vs. MTC
§ 100 98 99 
FTC
†
 vs. UTC
¶ 97 81 89 
†
FTC includes XTC1. 
‡
PTC includes K1 and TPC1. 
§
MTC includes CRL1803TT and MZCRC1. 
¶
UTC includes 8505C 
and C643.  
 
Table 7.  Performance of the PC-LDA classification model for discriminating the MTC from UTC cell 
lines. 
Comparison Sensitivity 
(%) 
Specificity 
(%) 
Diagnostic accuracy 
(%) 
CRG1803TT vs. 8505C 100 93 97 
MZCRC1 vs. 8505C 100 97 99 
CRG1803TT vs. C643 96 97 97 
MZCRC1 vs. C643 100 100 100 
MTC
†
 vs. UTC
‡ 78 90 84 
†
MTC includes CRL1803TT and MZCRC1. 
‡
UTC includes 8505C and C643. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Performance of the PC-LDA classification model for discriminating the benign and TC 
subtypes. 
Comparison Sensitivity (%) Specificity (%) 
Benign 57 98 
FTC
†
 94 92 
PTC
‡
 63 91 
UTC
¶
 79 96 
MTC
§
 100 96 
†
FTC includes XTC1. 
‡
PTC includes K1 and TPC1. 
¶
UTC includes 8505C and C643. 
§
MTC includes CRL1803TT and 
MZCRC1.  
 
 
Table 9. Performance of the PC-LDA classification model for discriminating the benign cell line from 
all TC lines. 
Comparison  Sensitivity 
(%) 
Specificity 
(%) 
Diagnostic 
accuracy (%) 
Benign vs TC
†
 74 87 81 
†
TC includes representative spectra from FTC, PTC, UTC, and MTC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure legends 
 
Figure 1. Mean Raman spectrum of the benign cell line (NThy-ori 3-1) with the standard deviation 
shown as shading, and the different spectral regions with corresponding biomolecules.  
Figure 2. Difference spectrum between (a) Nthy-ori 3-1 (benign) and FTC cell line XTC1; (b) Nthy-ori 
3-1 and PTC cell line K1; (c) Nthy-ori 3-1 and PTC cell line TPC1. Shading indicates regions of the 
spectrum that were significantly different (p<0.05). 
Figure 3. Difference spectrum between (a) Nthy-ori 3-1 (benign) and 8505C (UTC); and (b) Nthy-ori 
3-1 and C643 (UTC). Shading indicates regions of the spectrum that were significantly different 
(p<0.05). 
Figure 4. Difference spectrum between (a) Nthy-ori 3-1 (benign) and CRL1803TT (MTC); (b) Nthy-ori 
3-1 and MZCRC1 (MTC). Shading indicates regions of the spectrum that were significantly different 
(p<0.05). 
Figure 5. Scatter plot of the linear discriminant scores of the benign spectra and representative 
spectra from each TC subtype using PC-LDA. 
 





